Literature DB >> 17998672

Dendritic cells heterogeneity and its role in cancer immunity.

Kah-Wai Lin1, Tabarkiewicz Jacek, Rolinski Jacek.   

Abstract

Dendritic cells are the most potent 'professional' antigen-presenting cells, with high ability of primary immune response initiation. Dendritic cells originate from bone marrow progenitors, which circulate in peripheral blood and subsequently give rise to immature dendritic cells, which reside in peripheral tissues. When dendritic cells encounter danger signals, they undergo differentiation and maturation; thereafter they migrate to lymphatic tissues, where they synapse with T-cells and initiate primary immune response. The immune response efficiency is determined by Th1/Th2 balance. Although dendritic cells represent a rare group of leukocytes, their functional and phenotypical heterogeneity confer a great challenge to immunologists. In this review, the myeloid and lymphoid development pathways of dendritic cells, are discussed. The heterogeneity of dendritic cells will be reviewed, based on their anatomical locations, phenotypes and functions. This section focuses on blood and lymphoid tissue dendritic cells. Subsequently, the roles of dendritic cells in the immunity of cancer and how cancer bypasses the dendritic cell-mediated immune responses, are discussed.

Entities:  

Mesh:

Year:  2006        PMID: 17998672     DOI: 10.4103/0973-1482.25847

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  7 in total

1.  Phenotypic and functional comparison of two distinct subsets of programmable cell of monocytic origin (PCMOs)-derived dendritic cells with conventional monocyte-derived dendritic cells.

Authors:  Babak Beikzadeh; Nowruz Delirezh
Journal:  Cell Mol Immunol       Date:  2015-02-09       Impact factor: 11.530

2.  Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and in vivo.

Authors:  Yu-gang Wu; Guang-zhou Wu; Liang Wang; Yan-Yun Zhang; Zhong Li; De-Chun Li
Journal:  Med Oncol       Date:  2009-08-08       Impact factor: 3.064

3.  Immunosuppressive properties of human PD-1 + , PDL-1 + and CD80 + dendritic cells from lymph nodes aspirates of lung cancer patients.

Authors:  Iwona Kwiecień; Elżbieta Rutkowska; Agata Raniszewska; Rafał Sokołowski; Joanna Bednarek; Karina Jahnz-Różyk; Piotr Rzepecki; Joanna Domagała-Kulawik
Journal:  Cancer Immunol Immunother       Date:  2022-03-07       Impact factor: 6.630

4.  Tumor necrosis factor-α/CD40 ligand-engineered mesenchymal stem cells greatly enhanced the antitumor immune response and lifespan in mice.

Authors:  Somayeh Shahrokhi; Saeed Daneshmandi; Farid Menaa
Journal:  Hum Gene Ther       Date:  2014-03-04       Impact factor: 5.695

Review 5.  E-Selectin Ligands in the Human Mononuclear Phagocyte System: Implications for Infection, Inflammation, and Immunotherapy.

Authors:  Mariana Silva; Paula A Videira; Robert Sackstein
Journal:  Front Immunol       Date:  2018-01-19       Impact factor: 7.561

Review 6.  Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1).

Authors:  Federica Raggi; Maria Carla Bosco
Journal:  Cancers (Basel)       Date:  2020-05-23       Impact factor: 6.639

Review 7.  Tumor-derived microparticles in tumor immunology and immunotherapy.

Authors:  Jingwei Ma; Huafeng Zhang; Ke Tang; Bo Huang
Journal:  Eur J Immunol       Date:  2020-10-28       Impact factor: 5.532

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.